Study of PM060184 in Patients With Advanced Solid Tumors

Solid Tumors Clinical Trial

Official title:

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01299636
• Other study ID #: PM60184-A-002-10
• Status: Completed
• Phase: Phase 1
• First received: February 9, 2011
• Last updated: October 30, 2015
• Start date: January 2011
• Est. completion date: August 2015

Study information

• Verified date: October 2015
• Source: PharmaMar
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine the maximum tolerated dose and the recommended dose and to evaluate the safety and tolerability of PM060184.

Description:

This trial intends to determine the maximum tolerated dose and the recommended dose, to evaluate the safety and tolerability, to determine the pharmacokinetics and to evaluate the antitumor activity of PM060184 in patients with advanced solid tumors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria

1. Voluntary signed and dated written informed consent.

2. Patients with advanced solid tumors refractory to Standard therapy.

3. Age >/= 18 years.

4. Recovery from drug-related adverse events (AEs) of previous treatments, excluding alopecia.

5. Normal laboratory values within seven days prior to treatment administration.

6. Women of childbearing potential must have a negative serum pregnancy test before study entry. Both men and women must agree to use a medically acceptable method of contraception throughout the treatment period and for three months after discontinuation of treatment.

Exclusion criteria

1. Pregnant or lactating women.

2. Less than three weeks from radiation therapy or last dose of hormonal therapy, biological therapy or chemotherapy

3. Prior treatment with any investigational product less than 30 days prior to the first.

4. Central Nervous System metastases

5. Other relevant diseases or adverse clinical conditions:

• Increased cardiac risk:

• Presence of significant neurological or psychiatric disorders

• Neuropathy

• Active infection requiring treatment.

• Liver disease (e.g., cirrhosis, hepatitis).

• Immunocompromised patients.

• Any other major illness.

6. Limitation of the patient's ability to comply with the treatment.

7. Known hypersensitivity to any of the components of the drug product.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Solid Tumors

Intervention

Drug:
• PM060184
PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.

Locations

Country	Name	City	State
United States	START- South Texas Accelerated Research Therapeutics, LLC	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
PharmaMar

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD (maximum tolerated dose) and RD (recommended dose) of PM060184.	To determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM060184 administered on Days 1 and 8 of a 21-day cycle intravenously (i.v.) over 10 minutes to patients with advanced solid tumors.	From treatment onset to end of treatment	Yes
Secondary	To determine the pharmacokinetics of this drug in patients who have advanced solid tumors.	The complete plasma concentration-time profiles of PM06184 will be analyzed by standard non-compartmental methods.The percent of PM060184 total dose excreted unchanged into the urine over the collection interval will be calculated from the urine samples.	Blood samples will be collected up to 48 hours after the first infusion. At the RD, 24-h urine collection samples and 15 additional blood samples up to 48 hours after the second infusion of the first cycle.	No
Secondary	Antitumor activity	Antitumor activity will be measured according to the RECIST (Response Evaluation Criteria In Solid Tumors) version 1.1 or by evaluation of tumor markers	Every six weeks while on treatment. Patients who discontinued treatment without disease progression will be followed every three months until disease progression, other antitumor therapy, death or until the end-of-study date, whichever occurs first.	No